Bingham Private Wealth
REGN icon

Bingham Private Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Bingham Private Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$359K Buy
473
+17
+4% +$12.8K 0.24% 112
2026
Q2 		$284K Buy
456
+2
+0.4% +$1.36K 0.2% 135
2026
Q1 		$351K Buy
454
+37
+9% +$28.3K 0.28% 108
2025
Q4 		$322K Buy
+417
New +$283K 0.28% 106
2025
Q2 		$224K Buy
+427
New +$238K 0.21% 140

Other funds holding REGN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bingham Private Wealth's REGN Position: Q3 2026 in Review

Bingham Private Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 3.7% in Q3 2026, buying an estimated $12.8K and bringing the position to 473 shares worth $359K. The position accounts for 0.24% of the portfolio, ranked #112.

Bingham Private Wealth first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. 1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Bingham Private Wealth held 473 shares of Regeneron Pharmaceuticals worth $359K as of Q3 2026.
  • Bingham Private Wealth bought 17 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $12.8K.
  • Regeneron Pharmaceuticals made up 0.24% of Bingham Private Wealth's portfolio in Q3 2026, its #112 holding.
  • Bingham Private Wealth first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Bingham Private Wealth's 13F filing for Q3 2026, filed 5 Nov 2026.